ABSCINT specializes in advanced in vivo imaging diagnostics, focusing on developing innovative PET tracers using single-domain antibodies (sdAbs) for precision targeting. ABSCINT’s primary product is a specific anti-HER2 PET tracer, which enables comprehensive whole-body imaging for evaluating disease heterogeneity in HER2-low and HER2-positive breast cancer. This non-invasive technology offers rapid imaging results within 90 minutes, with minimal radiation exposure. This innovation also opens the door to HER2 reclassification via image-guided biopsies, enhancing diagnostic accuracy, patient care, and monitoring of treatment efficacy.

-- ABSCINT, Harnessing Antibody Scintigraphy for Precision Diagnostics in Breast Cancer and Beyond --

ABSCINT

Org chart

Teams

Offices